%0 Journal Article %T Etoposide-Cisplatin Alternating with Vinorelbine-Cisplatin Versus Etoposide-Cisplatin Alone in Patients with Extensive Disease Combined with Small Cell Lung Cancer %J Asian Pacific Journal of Cancer Prevention %I West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. %Z 1513-7368 %D 2014 %\ 10/01/2014 %V 15 %N 10 %P 4159-4163 %! Etoposide-Cisplatin Alternating with Vinorelbine-Cisplatin Versus Etoposide-Cisplatin Alone in Patients with Extensive Disease Combined with Small Cell Lung Cancer %K Combined small cell lung cancer %K Chemotherapy %K Efficacy %K etoposide-cisplatin %K vinorelbine-cisplatin %R %X Background: The aim of this study was to evaluate the efficacy of alternating etoposide-cisplatin andvinorelbine-cisplatin (EP-NP) compared with an etoposide-cisplatin (EP) regimen for advanced combined smallcell carcinomas. Materials and Methods: Histologically confirmed combined small cell carcinoma patients whomet the inclusion criteria were randomly assigned (1:1) into either the EP-NP setting (group A) or the EP setting(group B). The primary endpoint was progression-free survival in patients who received at least one dose oftreatment. Results: Eighty-two patients entered into this trial, 42 in group A and 40 in group B. The objectiveresponse rates in group A and group B were 42.9% and 32.5%, respectively (p=0.334). Survival analysis showedthat median progression-free survival was 6.1 months in group A, which was significantly longer than the 4.1months in group B (p=0.041). However, as to overall survival, no significant difference was found between the twogroups (11.0 vs 10.1 months in groups A and B, respectively, p=0.545). No unexpected side effects were observedin either group. Conclusions: The EP-NP regimen for combined small cell carcinomas prolonged progressionfreesurvival compared with the EP regimen. Further clinical investigations are warranted. %U https://journal.waocp.org/article_29216_ccc90548dce2fa1f75a47e6b652c5958.pdf